Marathon Asset Management Ltd Has $34.18 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Marathon Asset Management Ltd raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.3% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 68,635 shares of the medical research company's stock after buying an additional 4,042 shares during the quarter. Marathon Asset Management Ltd's holdings in Thermo Fisher Scientific were worth $34,182,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Confluence Wealth Services Inc. raised its stake in Thermo Fisher Scientific by 71.4% during the first quarter. Confluence Wealth Services Inc. now owns 4,518 shares of the medical research company's stock valued at $2,248,000 after buying an additional 1,882 shares in the last quarter. Highland Capital Management LLC raised its stake in Thermo Fisher Scientific by 3.0% during the first quarter. Highland Capital Management LLC now owns 35,006 shares of the medical research company's stock valued at $17,419,000 after buying an additional 1,027 shares in the last quarter. Mcdaniel Terry & Co. raised its stake in Thermo Fisher Scientific by 1.4% during the first quarter. Mcdaniel Terry & Co. now owns 30,674 shares of the medical research company's stock valued at $15,263,000 after buying an additional 434 shares in the last quarter. BSW Wealth Partners raised its position in shares of Thermo Fisher Scientific by 13.2% during the 1st quarter. BSW Wealth Partners now owns 1,457 shares of the medical research company's stock worth $725,000 after purchasing an additional 170 shares during the period. Finally, Mascoma Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 19.3% during the 1st quarter. Mascoma Wealth Management LLC now owns 1,236 shares of the medical research company's stock worth $615,000 after purchasing an additional 200 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Stifel Nicolaus dropped their price target on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Robert W. Baird dropped their price target on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Scotiabank dropped their price target on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research report on Friday, April 25th. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Finally, Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $604.05.

Thermo Fisher Scientific Price Performance

TMO stock traded down $4.45 during trading hours on Friday, hitting $407.67. 3,922,604 shares of the stock traded hands, compared to its average volume of 2,584,448. The stock has a 50-day simple moving average of $409.74 and a 200 day simple moving average of $483.23. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The company has a market cap of $153.89 billion, a P/E ratio of 18.64, a P/E/G ratio of 2.17 and a beta of 0.78. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. During the same quarter last year, the business posted $5.11 earnings per share. The company's quarterly revenue was up .2% on a year-over-year basis. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a $0.43 dividend. The ex-dividend date is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.42%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.